These alterations are important as they are driving current marker-based phase III clinical trials testing specific agents targeting these alterations in FGFR2 fusion-positive CCA (NCT03773302)123,124 and IDH-mutated CCA (NCT02989857). Here, IDH2 is linked to cholangiocarcinoma.